Benign Hematology
Expertise in Non-Malignant Hematology for Clinical Trials
Established in 1973 with the founding of the Platelet and Neutrophil Immunology Laboratory, Versiti Diagnostic Laboratories have a rich history of innovation in diagnostic testing for bleeding, clotting, platelet and neutrophil disorders. Versiti’s hematology laboratories include the Hemostasis Reference Laboratory, Platelet and Neutrophil Immunology Laboratory, and Hematology Genetics Program, which collectively serve nearly 80% of hemophilia treatment centers (HTCs) in the United States. With our deep understanding of the clinical trials landscape, we combine diagnostic testing, assay development, and regulatory support to help bring clinical breakthroughs to patients—ensuring timely and impactful solutions.
A Trusted Laboratory Partner for Rare, Non-Malignant Hematologic Diseases
In partnership with Versiti Blood Research Institute, our labs have led the research and development of numerous groundbreaking diagnostic assays for rare and ultra-rare bleeding and clotting disorders. Versiti’s specialized focus in non-malignant hematology includes research and diagnostic services for diseases including:
- von Willebrand disease
- Hemophilia
- Thrombotic microangiopathy
- Thrombocytopenia
- Fetal and neonatal alloimmune neutropenia (FNAIT)
Our team of non-malignant hematology experts includes laboratory and medical directors, scientists, researchers, and more, with decades of experience and expertise in these complex disease states.
Ken Friedman, MD
Dr. Friedman is an investigator and senior medical director of hematology at Versiti Comprehensive Center for Bleeding Disorders.
Sandra L. Haberichter, PhD
Dr. Haberichter is a director of hemostasis and senior investigator whose lab is focused on defining the mechanisms that cause Von Willebrand disease (VWD).
Sarah Mueller, MD, PhD
Dr. Mueller is a Medical Director of Diagnostic Hematology.
Brian Curtis, PhD, D(ABMLI), MT(ASCP), SBB
Dr. Curtis is the senior director of diagnostic hematology and director of the Platelet & Neutrophil Immunology Lab.
Versiti Blood Research Institute’s Hemostasis, Thrombosis & Vascular Biology program includes basic and clinical research and is home to multiple important breakthroughs in understanding the mechanisms of the regulation of blood clotting. The work of Versiti’s clinical investigators has led to improved outcomes for patients with blood-related diseases, including sickle cell disease, hemophilia and Vvon Willebrand disease.
As part of our ongoing commitment to clinical research, Versiti Blood Research Institute is a proud supporter of the Venous thromboEmbolism Network U.S. (VENUS), the only collaborative clinical trial research network in the U.S. focused on venous thrombosis, including venous thromboembolism (VTE) and pulmonary embolism (PE).